Show simple item record

dc.contributor.authorMishra, Alok K
dc.contributor.authorBanday, Shahid
dc.contributor.authorBharadwaj, Ravi
dc.contributor.authorAli, Amjad
dc.contributor.authorRashid, Romana
dc.contributor.authorKulshreshtha, Ankur
dc.contributor.authorMalonia, Sunil K
dc.date.accessioned2024-04-26T20:18:50Z
dc.date.available2024-04-26T20:18:50Z
dc.date.issued2022-12-26
dc.identifier.citationMishra AK, Banday S, Bharadwaj R, Ali A, Rashid R, Kulshreshtha A, Malonia SK. Macrophages as a Potential Immunotherapeutic Target in Solid Cancers. Vaccines (Basel). 2022 Dec 26;11(1):55. doi: 10.3390/vaccines11010055. PMID: 36679900; PMCID: PMC9863216.en_US
dc.identifier.issn2076-393X
dc.identifier.doi10.3390/vaccines11010055en_US
dc.identifier.pmid36679900
dc.identifier.urihttp://hdl.handle.net/20.500.14038/53321
dc.description.abstractThe revolution in cancer immunotherapy over the last few decades has resulted in a paradigm shift in the clinical care of cancer. Most of the cancer immunotherapeutic regimens approved so far have relied on modulating the adaptive immune system. In recent years, strategies and approaches targeting the components of innate immunity have become widely recognized for their efficacy in targeting solid cancers. Macrophages are effector cells of the innate immune system, which can play a crucial role in the generation of anti-tumor immunity through their ability to phagocytose cancer cells and present tumor antigens to the cells of adaptive immunity. However, the macrophages that are recruited to the tumor microenvironment predominantly play pro-tumorigenic roles. Several strategies targeting pro-tumorigenic functions and harnessing the anti-tumorigenic properties of macrophages have shown promising results in preclinical studies, and a few of them have also advanced to clinical trials. In this review, we present a comprehensive overview of the pathobiology of TAMs and their role in the progression of solid malignancies. We discuss various mechanisms through which TAMs promote tumor progression, such as inflammation, genomic instability, tumor growth, cancer stem cell formation, angiogenesis, EMT and metastasis, tissue remodeling, and immunosuppression, etc. In addition, we also discuss potential therapeutic strategies for targeting TAMs and explore how macrophages can be used as a tool for next-generation immunotherapy for the treatment of solid malignancies.en_US
dc.language.isoenen_US
dc.relation.ispartofVaccinesen_US
dc.relation.urlhttps://doi.org/10.3390/vaccines11010055en_US
dc.rightsCopyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).; Attribution 4.0 Internationalen_US
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectCAR macrophagesen_US
dc.subjectCD47en_US
dc.subjectCSF1Ren_US
dc.subjectTAMsen_US
dc.subjectcancer stem cellsen_US
dc.subjectclinical trialsen_US
dc.subjectdrug resistanceen_US
dc.subjectimmunotherapyen_US
dc.subjectinflammationen_US
dc.subjectmetastasisen_US
dc.subjectphagocytosisen_US
dc.subjectprognosisen_US
dc.titleMacrophages as a Potential Immunotherapeutic Target in Solid Cancersen_US
dc.typeJournal Articleen_US
dc.source.journaltitleVaccines
dc.source.volume11
dc.source.issue1
dc.source.countrySwitzerland
dc.identifier.journalVaccines
refterms.dateFOA2024-04-26T20:18:52Z
dc.contributor.departmentMedicineen_US
dc.contributor.departmentMolecular, Cell and Cancer Biologyen_US


Files in this item

Thumbnail
Name:
vaccines-11-00055-v3.pdf
Size:
2.980Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).; Attribution 4.0 International
Except where otherwise noted, this item's license is described as Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).; Attribution 4.0 International